Halozyme Therapeutics (NASDAQ:HALO) Receives “Buy” Rating from HC Wainwright

Halozyme Therapeutics (NASDAQ:HALO)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a research note issued on Friday, Benzinga reports. They presently have a $65.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s price target suggests a potential upside of 7.37% from the company’s previous close.

A number of other research firms have also commented on HALO. The Goldman Sachs Group upped their price target on Halozyme Therapeutics from $44.00 to $49.00 and gave the company a “neutral” rating in a research report on Monday, July 22nd. Morgan Stanley increased their target price on shares of Halozyme Therapeutics from $59.00 to $64.00 and gave the company an “overweight” rating in a research report on Wednesday, August 7th. Piper Sandler lowered shares of Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and raised their price target for the stock from $48.00 to $51.00 in a report on Friday, June 7th. Wells Fargo & Company upped their price objective on shares of Halozyme Therapeutics from $48.00 to $58.00 and gave the company an “overweight” rating in a research note on Friday, June 7th. Finally, JPMorgan Chase & Co. decreased their price objective on shares of Halozyme Therapeutics from $53.00 to $52.00 and set an “overweight” rating for the company in a research report on Tuesday, August 6th. Two investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat.com, Halozyme Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $59.44.

Halozyme Therapeutics Stock Up 1.9 %

HALO stock opened at $60.54 on Friday. The stock has a market capitalization of $7.67 billion, a P/E ratio of 25.02, a price-to-earnings-growth ratio of 0.57 and a beta of 1.28. The company has a current ratio of 7.41, a quick ratio of 6.21 and a debt-to-equity ratio of 5.19. The firm has a 50-day moving average price of $57.18 and a 200-day moving average price of $48.18. Halozyme Therapeutics has a 12 month low of $32.83 and a 12 month high of $65.53.

Halozyme Therapeutics (NASDAQ:HALO) last issued its earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.91 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.73 by $0.18. Halozyme Therapeutics had a return on equity of 195.80% and a net margin of 38.62%. The business had revenue of $231.40 million during the quarter, compared to analysts’ expectations of $204.94 million. During the same quarter in the prior year, the firm earned $0.68 EPS. The business’s revenue for the quarter was up 4.7% compared to the same quarter last year. As a group, equities research analysts anticipate that Halozyme Therapeutics will post 3.7 EPS for the current fiscal year.

Insider Buying and Selling at Halozyme Therapeutics

In related news, CFO Nicole Labrosse sold 10,000 shares of the stock in a transaction on Thursday, June 27th. The stock was sold at an average price of $51.93, for a total value of $519,300.00. Following the sale, the chief financial officer now owns 15,480 shares in the company, valued at $803,876.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other news, Director Matthew L. Posard sold 9,881 shares of the business’s stock in a transaction that occurred on Wednesday, August 14th. The stock was sold at an average price of $57.70, for a total transaction of $570,133.70. Following the transaction, the director now directly owns 69,874 shares of the company’s stock, valued at $4,031,729.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Nicole Labrosse sold 10,000 shares of the firm’s stock in a transaction on Thursday, June 27th. The stock was sold at an average price of $51.93, for a total value of $519,300.00. Following the completion of the sale, the chief financial officer now directly owns 15,480 shares of the company’s stock, valued at approximately $803,876.40. The disclosure for this sale can be found here. Insiders have sold 74,881 shares of company stock valued at $4,267,884 in the last 90 days. 2.40% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Halozyme Therapeutics

A number of large investors have recently modified their holdings of the stock. International Assets Investment Management LLC purchased a new position in shares of Halozyme Therapeutics in the 4th quarter valued at approximately $1,030,000. Private Advisor Group LLC increased its stake in shares of Halozyme Therapeutics by 6.2% during the fourth quarter. Private Advisor Group LLC now owns 23,451 shares of the biopharmaceutical company’s stock valued at $867,000 after purchasing an additional 1,377 shares in the last quarter. Principal Securities Inc. purchased a new position in shares of Halozyme Therapeutics during the fourth quarter valued at approximately $34,000. Dimensional Fund Advisors LP grew its stake in shares of Halozyme Therapeutics by 9.9% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,613,113 shares of the biopharmaceutical company’s stock worth $59,622,000 after buying an additional 145,879 shares during the last quarter. Finally, Vanguard Personalized Indexing Management LLC raised its holdings in Halozyme Therapeutics by 86.0% in the fourth quarter. Vanguard Personalized Indexing Management LLC now owns 20,050 shares of the biopharmaceutical company’s stock worth $741,000 after buying an additional 9,272 shares during the last quarter. Institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.